AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie unrecognized Tax Benefits (UTB) — Ending Balance [year-end] ($M) ($M)
Form 10-K Note 14 Income Taxes
Latest, FY2025
4,505
Period ended Dec 31, 2025
Change on a year earlier
+2.4%
4,401 in FY2024
History
11 years
Since FY2015
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unrecognized Tax Benefits (UTB) — Ending Balance [year-end] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,505 | +2.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 4,401 | -23.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 5,762 | +1.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 5,670 | +3.3% | Form 10-K (filed 2026-02-20) ↗ |
| FY2021 | Dec 31, 2021 | 5,489 | +4.3% | Form 10-K (filed 2025-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 5,264 | +97.8% | Form 10-K (filed 2024-02-20) ↗ |
| FY2019 | Dec 31, 2019 | 2,661 | -6.7% | Form 10-K (filed 2023-02-17) ↗ |
| FY2018 | Dec 31, 2018 | 2,852 | +5.6% | Form 10-K (filed 2022-02-18) ↗ |
| FY2017 | Dec 31, 2017 | 2,701 | +131.3% | Form 10-K (filed 2021-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 1,168 | +22.4% | Form 10-K (filed 2020-02-21) ↗ |
| FY2015 | Dec 31, 2015 | 954 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up unrecognized tax benefits (utb) — ending balance [year-end] ($m)
- UTB Rollforward — Increases for Current Year Tax Positions ($M)337 · FY2025
- UTB Rollforward — Increases for Prior Year Tax Positions ($M)20 · FY2025
- UTB Rollforward — Increases from Business Combinations ($M)12 · FY2025
- UTB Rollforward — Decreases for Prior Year Tax Positions ($M)18 · FY2025
- UTB Rollforward — Decreases from Settlements with Taxing Authorities ($M)222 · FY2025
- UTB Rollforward — Decreases from Lapse of Statute of Limitations ($M)25 · FY2025
- UTB — Portion That Would Affect Effective Tax Rate ($M)4,400 · FY2025
- UTB — Accrued Interest and Penalties Liability ($M)1,700 · FY2025
- UTB — Interest and Penalties Expense Recognized ($M)315 · FY2025
- UTB — Total Balance Sheet Liability Including Interest & Penalties ($M)5,573 · FY2025
Cite this data
StockData. (2026). AbbVie Unrecognized Tax Benefits (UTB) — Ending Balance [year-end] ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/utb_end_tot
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.